PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1532530
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1532530
Cancer Immunotherapy Market Size - By Product (Monoclonal Antibodies, Cancer Vaccines, Immunomodulators, Oncolytic Viral Therapies, Cytokines), Cancer Type (Lung, Breast, Colorectal, Prostate, Pancreatic), End-use & Forecast, 2024 - 2032
Global Cancer Immunotherapy Market will witness over 9.3% CAGR between 2024 and 2032, catapulted by the escalating cancer incidence, bolstering the demand for advanced and effective treatment options.
Immunotherapy, which harnesses the body's immune system to target and destroy cancer cells, offers a promising alternative to traditional treatments. Advancements in biotechnology and molecular medicine have led to the development of innovative immunotherapy drugs that offer improved efficacy and fewer side effects compared to traditional treatments. Additionally, substantial investments in R&D by pharmaceutical companies and favorable regulatory policies are accelerating the approval and commercialization of new immunotherapy products. For instance, in June 2024, the FDA approved Merck's KEYTRUDA(R) pembrolizumab combined with carboplatin and paclitaxel as treatment for advanced or recurrent endometrial carcinoma.
The cancer immunotherapy market is segmented based on product, cancer type, end-use, and region.
The immunomodulators segment will showcase a noteworthy CAGR through 2032, due to a growing emphasis on personalized medicine and the need for therapies that can modulate the immune system effectively. Immunomodulators enhance the body's natural defenses against cancer, leading to more tailored and potentially effective treatment options. Additionally, as research reveals the complex interactions between cancer and the immune system, there is a heightened focus on developing therapies that can specifically target these mechanisms. This growing understanding and the quest for more precise and adaptive treatments catapult the demand for immunomodulators.
The lung cancer segment will hold a promising cancer immunotherapy market share by 2032, driven by the high unmet medical need and the complex nature of the disease. Lung cancer, with its high mortality rate and diverse subtypes, presents significant challenges for effective treatment. Immunotherapy offers a promising alternative by targeting specific cancer cells and potentially improving patient outcomes. The continued R&D efforts aimed at innovative treatments for lung cancer will drive the segment growth.
North America cancer immunotherapy market will exhibit a promising CAGR during the forecast period. Advanced healthcare infrastructure and high levels of research funding facilitate rapid development and adoption of new therapies. The regions well-established pharmaceutical and biotech industries contribute to swift innovation and regulatory approvals. Additionally, increasing public and private investments in cancer research, coupled with a rising prevalence of cancer cases, heighten the demand for effective treatments. The strong emphasis on personalized medicine and patient access to modern therapies will spur the adoption of immunotherapy solutions across the region.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360°synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of cancer
- 3.2.1.2 Advancements in research and development
- 3.2.1.3 Personalized medicine and biomarker development
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High treatment costs
- 3.2.2.2 Risk of side effects associated with the treatment
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Technological landscape
- 3.5 Regulatory landscape
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Competitive positioning matrix
- 4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Monoclonal antibodies
- 5.3 Cancer vaccines
- 5.4 Immunomodulators
- 5.4.1 Checkpoint inhibitors
- 5.4.2 Immune checkpoint modulators
- 5.4.3 Other immunomodulators
- 5.5 Cytokines
- 5.6 Oncolytic viral therapies
Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Lung cancer
- 6.3 Breast cancer
- 6.4 Colorectal cancer
- 6.5 Melanoma
- 6.6 Prostate cancer
- 6.7 Pancreatic cancer
- 6.8 Other cancer types
Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Specialty clinics
- 7.4 Cancer research centers
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 AbbVie Inc.
- 9.2 Amgen Inc.
- 9.3 AstraZeneca PLC
- 9.4 Bayer AG
- 9.5 Bristol-Myers Squibb Company
- 9.6 Celldex Therapeutics, Inc.
- 9.7 Eli Lilly and Company
- 9.8 F. Hoffmann-La Roche Ltd.
- 9.9 Gilead Sciences, Inc.
- 9.10 GSK plc
- 9.11 Immunocore Holdings plc
- 9.12 Johnson & Johnson
- 9.13 Merck & Co., Inc
- 9.14 Novartis AG
- 9.15 Pfizer Inc.
